Angiogenesis as an immunopharmacologic target in inflammation and cancer

Int Immunopharmacol. 2004 Nov;4(12):1537-47. doi: 10.1016/j.intimp.2004.07.017.

Abstract

Many pathological processes including wound healing, chronic inflammation and cancer require angiogenesis, i.e., the formation of new vasculature in the lesions. Accumulating evidence indicates that angiogenesis is crucial for both chronic inflammation and the growth of malignant tumors with the participation of diverse cytokines, chemokines and growth factors. It is nevertheless believed that differences exist in angiogenesis between cancer and chronic inflammatory diseases. The aim of this review is to outline the characteristics of angiogenesis in chronic inflammation and cancer. A better understanding of the angiogenic processes may facilitate the design of more effective therapies for chronic inflammation and cancer.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / pharmacology*
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Endothelial Cells / drug effects
  • Endothelial Cells / immunology
  • Humans
  • Inflammation / immunology
  • Inflammation / therapy*
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Neovascularization, Pathologic / immunology*
  • Neovascularization, Pathologic / therapy*

Substances

  • Angiogenesis Inhibitors